We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App





QuidelOrtho Highlights Innovative Point-of-Care Diagnostic Solutions

By LabMedica International staff writers
Posted on 21 May 2023

QuidelOrtho Corporation (San Diego, CA, USA) is highlighting the latest advances in laboratory testing and point-of-care diagnostics at the Euromedlab Congress in Rome. More...

The company is demonstrating how effectively combining point-of-care and laboratory testing can enhance patient care and improve overall healthcare outcomes. QuidelOrtho’s advanced lab management tools and expertise can help labs streamline their workflow, automate operations, and efficiently analyze data, thereby enhancing overall efficiency without compromising on quality.

At EuroMedLab Rome 2023, the company is demonstrating Savanna – a true sample-to-result point-of-care multiplex molecular solution. The cutting-edge system can accurately and simultaneously test for SARS-CoV-2, Flu A, Flu B, and RSV on a panel within 20 minutes. Besides delivering rapid results, the RVP4 also delivers superior clinical performance and possesses the capability to detect SARS-CoV-2 variants. Additionally, QuidelOrtho is demonstrating how its Vitros XT 7600 Integrated System can boost lab efficiency, offering a wide-ranging menu of over 160 assays, thus future-proofing labs and preparing them for potential Vitros Automation incorporation. This system is also time-efficient, with a first-pass yield of 96.5% and incorporates E-Connectivity Technology for uninterrupted operation. The company's innovative waterless system further maximizes lab space and enhances productivity.

Among QuidelOrtho’s innovative point-of-care solutions being featured at the industry event is the TriageTrue High Sensitivity Troponin I Test. This revolutionary test empowers medical professionals to make informed decisions that lead to better patient outcomes and overall improved healthcare efficiency. The test merges ER and lab testing, delivering high diagnostic precision with results available in under 20 minutes. The quick results can expedite patient handling, minimize hospital stay duration, and enhance ED throughput. In addition, QuidelOrtho is participating in the Euromedlab 2023 Satellite Meeting - Point-of-Care Testing: Home, Hospital and Beyond event. The company’s Vendor Talk by Dr. Holger Gundelach, Head of EMEA POC-IA Business Unit and Clinical Value at QuidelOrtho, on "The time is now – Accelerate patient management at the point-of-care" will be providing valuable insights and exploring the future of point-of-care testing.

Related Links:
QuidelOrtho Corporation 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.